摘要
目的观察白芍总苷胶囊(TGP)治疗小儿过敏性紫癜(HSP)的临床疗效及安全性评价。方法 2012年在本院选择诊断明确的过敏性紫癜患儿40例,随机分为治疗组和对照组,对照组按常规治疗,治疗组在常规治疗的基础上加用TGP,观察2组的临床疗效、预后及复发情况。结果治疗组患儿的总有效率(95.0%)与对照组有效率(90.0%)无显著性差异,但其治愈率(85.0%)明显高于对照组的55%(P<0.05),3个月内的复发率明显低于对照组,临床症状:皮疹消退、关节痛缓解及腹痛缓解的时间均明显低于对照组。在不良反应发生方面:治疗组仅出现轻度的腹泻,且发生率较低,而对照组患儿部分出现了肝功能的异常。结论白芍总苷能较好地缓解HSP患儿的症状,缩短患儿症状改善的时间,且不良反应发生率低,患儿耐受性好。
Objective To observe the efficacy and safety of TGP treatment in j henoch-schonlein purpura （HSP）. Methods A total of 30 patients who were diagnosed HSP in pediatrics were selected. The patients were randomly divided into 2 groups, one was treated with secundum artem, the other was treated with TGP and secundum artem. Results The total effective in treatment group （95%） and the control group （90%） had no significant difference, but the cure rate （85%） was higher than that in the control group 55% （P 〈 0. 05 ）. The relapse rate was significantly lower than that of the control group within 3 months. The clinical symptoms ： skin rash subsided, joint pain and abdominal pain relief time were significantly lower than that of the control group. The adverse reactions that occurred in the treatment group were only mild diarrhoea, and low incidence rate, while in children of the control group was abnormal liver function. Conclusion Total glucosides of paeonia can effectively alleviate the symptoms of HSP patients, symptoms improved time is shortened, and the incidence of adverse reactions are low, with good tolerance.
出处
《今日药学》
CAS
2013年第9期581-583,共3页
Pharmacy Today
关键词
白芍总苷
过敏性紫癜
小儿
临床疗效
安全性
henoch-schonlein purpura （HSP）
total gtuco sides of paeonia （TGP）
children
clinical efficacy
safety
